Get the Stockscreener App
47.48
4.89%
-2.44
After Hours:
48.12
0.64
+1.35%
Dianthus Therapeutics Inc stock is traded at $47.48, with a volume of 539.61K.
It is down -4.89% in the last 24 hours and up +21.37% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$49.92
Open:
$50.1
24h Volume:
539.61K
Relative Volume:
0.69
Market Cap:
$2.05B
Revenue:
$4.85M
Net Income/Loss:
$-114.75M
P/E Ratio:
-14.61
EPS:
-3.25
Net Cash Flow:
$-100.36M
1W Performance:
+1.93%
1M Performance:
+21.37%
6M Performance:
+138.59%
1Y Performance:
+106.35%
1-Day Range:
$45.64
$50.10
1-Week Range:
$45.64
$53.33
52-Week Range:
$13.37
$57.50
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
47.48 | 2.16B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | Truist | Buy |
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
DNTH: Key 2026 clinical milestones and strong commercial outlook drive optimism for pipeline success - TradingView
DNTH: Pivotal trial readouts and strong financials position the pipeline for major commercial impact - TradingView
What 4 Analyst Ratings Have To Say About Dianthus Therapeutics - Benzinga
Wedbush Boosts Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $55.00 - MarketBeat
Candriam S.C.A. Purchases 60,852 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat
How Investors Are Reacting To Dianthus Therapeutics (DNTH) US$600 Million Universal Shelf Registration - simplywall.st
Assessing Dianthus Therapeutics (DNTH) Valuation After New US$600m Shelf Registration Filing - Sahm
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - 富途牛牛
Dianthus Therapeutics (DNTH) Price Target Increased by 10.51% to 75.99 - Nasdaq
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Update - MarketBeat
Jefferies Financial Group Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Given New $81.00 Price Target at Jefferies Financial Group - MarketBeat
Biotech Stocks To Follow Today – January 30th - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biotech Stocks To Follow TodayJanuary 30th - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 54.05 USD By Investing.com - Investing.com India
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: A Biotech Gem with 21.98% Upside Potential - DirectorsTalk Interviews
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 52-Week HighShould You Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 54.05 USD - Investing.com
Oppenheimer Boosts Price Target on Dianthus Therapeutics to $125 From $62, Keeps Outperform Rating - marketscreener.com
Oppenheimer raises Dianthus Therapeutics stock price target to $125 from $62 - Investing.com Canada
Dianthus Therapeutics may issue up to $600 million in securities - marketscreener.com
Dianthus Therapeutics May Issue Up To $600 Million In Securities - TradingView
Dianthus Therapeutics (DNTH) Is Up 18.7% After Claseprubart Trial Progress Reshapes Its Autoimmune Focus - Sahm
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: Exploring a Potential 23% Upside in the Biotech Sector - DirectorsTalk Interviews
Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last? - Nasdaq
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 10.3%What's Next? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 46.6 USD By Investing.com - Investing.com India
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month HighShould You Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 46.6 USD - Investing.com
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Up 47.4% in December - MarketBeat
First Week of March 20th Options Trading For Dianthus Therapeutics (DNTH) - Nasdaq
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.1%Should You Sell? - MarketBeat
Published on: 2026-01-15 20:27:08 - baoquankhu1.vn
Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Is Dianthus Therapeutics Inc. currently under institutional pressureJuly 2025 Setups & Growth Oriented Trading Recommendations - bollywoodhelpline.com
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year HighShould You Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at $45.56 By Investing.com - Investing.com Nigeria
Trading Recap: How Dianthus Therapeutics Inc stock reacts to bond yieldsWeekly Stock Summary & Free Safe Capital Growth Stock Tips - Bộ Nội Vụ
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 12%Here's What Happened - MarketBeat
Breakout Zone: Whats the RSI of Dianthus Therapeutics Inc stock2025 Risk Factors & High Accuracy Swing Trade Signals - baoquankhu1.vn
Dianthus Therapeutics stock hits 52-week high at $45.56 - Investing.com
Fed Watch: How Dianthus Therapeutics Inc stock responds to policy changesJuly 2025 Snapshot & Weekly High Momentum Picks - Bộ Nội Vụ
Assessing Dianthus Therapeutics (DNTH) Valuation As Price To Book Sits Near 3x And Shares Show Mixed Returns - Yahoo Finance
Truist Financial Sticks to Its Buy Rating for Dianthus Therapeutics (DNTH) - The Globe and Mail
Will Dianthus Therapeutics Inc. stock gain from lower inflation2025 Institutional Moves & Low Risk Profit Maximizing Plans - Улправда
Can Dianthus Therapeutics Inc. stock hit record highs againJuly 2025 Sentiment & Risk Managed Investment Entry Signals - Улправда
Why Dianthus Therapeutics Inc. stock could outperform in 2025Portfolio Update Summary & Real-Time Volume Triggers - Улправда
DNTH: Analyst Raises Price Target to $63, Maintains Buy Rating | - GuruFocus
Truist Financial Raises Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $63.00 - MarketBeat
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dianthus Therapeutics Inc Stock (DNTH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Savitz Ryan | CFO & CBO |
Dec 04 '25 |
Sale |
45.18 |
20,000 |
903,600 |
0 |
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):